Seasonality of hypercalcemia

- A population-based study on Funen sarcoidosis patients





J. E. Rødsgaard¹, D. P. Henriksen², C. B. Laursen^{1,3}, J.R. Davidsen^{1,3}

¹ Department of Respiratory Medicine, Odense University Hospital; Department of Clinical Research, University of Southern Denmark - Odense (Denmark)

² Department of Clinical Biochemistry and Pharmacology, Odense University Hospital; Department of Public Health, University of Southern Denmark - Odense (Denmark)

³ South Danish Center for Interstitial Lung Diseases, Odense University Hospital - Odense (Denmark)

Introduction

Sarcoidosis-associated hypercalcemia presents in 5-10% of sarcoidosis patients.

Pulmonary alveolar macrophages express 1-alphahydroxylase, the enzyme responsible for the conversion of excess active vitamin D.

Previous research indicates seasonal variation in the incidence of sarcoidosis and the vitamin D concentration.

This study aimed to investigate potential seasonal variation in hypercalcemia in sarcoidosis patients living on Funen (Denmark).

Results n=787 n=125 (15,9%) Sarcoidosis patients included Sarcoidosis patients with hypercalcemia (cases) Male:female ratio Median age

Method

Funen laboratory cohort (FLaC) consists of all residents on Funen who had a creatinine measurement performed between January 2000 and December 2015.

The study period was dependent on the sun data acquired from Danish Meteorological Institute and was consequently from 2004-2015.

Hypercalcemia was classified as a calcium measurement above 1,32 mmol/L within one year of diagnosis.




Fig. 1: Flowchart of patient identification




Fig. 2: Incidence of hypercalcemia related to the median number of sun hours per month in Odense Municipality from 2004-2015




Fig. 3: The absolute difference in percent (%) per month in ionised calcium. Black represents calcium concentration in cases and grey represents the rest of the cohort.

Conclusion

Hypercalcemia among Funen sarcoidosis patients clearly indicates a seasonal distribution with a peak from April to September. The physician should inform sarcoidosis patients at risk on this issue, in order to take their precautions to prevent development of potential symptomatic hypercalcemia.